Kopra Bio develops novel cancer immunotherapy treatments. Their approach engineers cancer cells to function as internal biofactories. This process is designed to trigger the self-destruction of the malignant cells.
Funding
$500K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional cancer treatments often struggle to target cancer cells specifically, leading to systemic toxicity and limited efficacy. Developing personalized therapies that can adapt to the unique characteristics of individual tumors remains a significant challenge.
Solution
Kopra is developing a viral immunotherapy platform that leverages oncolytic viruses to selectively infect and destroy cancer cells. These infected cells are then transformed into "biofactories" that produce therapeutic proteins, effectively turning the tumor against itself. This approach aims to deliver personalized cancer treatments by targeting specific cancer types and stimulating a robust immune response. The technology has the potential to improve patient outcomes by enhancing treatment efficacy and reducing off-target effects.
Target Audience
The primary target audience includes cancer patients, oncologists, and researchers seeking innovative and personalized cancer immunotherapy solutions.
Features
- Oncolytic virus-based platform for targeted cancer cell infection and destruction
- Conversion of cancer cells into therapeutic protein-producing biofactories
- Personalized treatment approach tailored to specific cancer types
- Induction of a strong anti-tumor immune response